ABSTRACT Background: Evidence from animal and observational studies has supported the beneficial effects of soy intake on glycemic control, but intervention studies in humans have generated mixed results and have not been systematically examined. Objective: We aimed to quantitatively evaluate the effects of soy intake on measures of glycemic control. Design: We conducted a structured electronic search of PubMed, EMBASE, the Cochrane Library, and the China National Knowledge Infrastructure (updated to March 2010) databases for randomized controlled trials that described the effectiveness of different soy regimes on measures of glycemic control [homeostatic model assessment of insulin resistance (HOMA-IR) and fasting glucose and insulin, glycated hemoglobin (Hb A 1c ), and 2-h glucose and insulin concentrations]. Data on participants, interventions, outcomes, and potential effect modifiers were extracted independently. Weighted mean effect sizes were calculated for net changes by using fixedeffects or random-effects models. We performed prespecified subgroup analyses to explore the influence of covariates on net changes of fasting glucose and insulin concentrations. Results: Twenty-four trials with a total of 1518 subjects were included in the meta-analysis. Soy consumption did not significantly affect measures of glycemic control. The mean (95% CI) difference was 20.69 mg/dL (21.65, 0.27 mg/dL) for fasting glucose concentrations in the fixed-effects model (P = 0.16) and 20.18 mg/dL (20.70, 0.34 mg/dL) for fasting insulin concentrations in the random-effects model (P = 0.50). Significant heterogeneity was noted in the results of fasting insulin concentrations and HOMA-IR. Conclusions: There was not a significant overall effect of soy intake on improvements of fasting glucose and insulin concentrations; however, a favorable change in fasting glucose concentrations was observed in studies that used whole soy foods or a soy diet in the subgroup analysis. Evidence for other glycemic variables such as Hb A 1c and 2-h postchallenge glucose and insulin concentrations was limited because of the small number of trials.
INTRODUCTION
Diabetes is an increasing public health concern. The appropriate management of hyperglycemia by lifestyle modifications can reduce the complications and morbidity of diabetes. Soy has long been a staple of the Asian diet. Soybean is a rich source of vegetable protein, complex carbohydrates, polyunsaturated fat, soluble fibers, and phytoestrogens (isoflavones) that may be beneficial in the prevention of diabetes (1) . In vitro studies suggest that isoflavones have antidiabetic properties such as the inhibition of the intestinal brush border uptake of glucose, a-glucosidase inhibitor actions, and tyrosine kinase inhibitory properties (2, 3) . Animal studies have indicated that soy protein or isoflavones improve glycemic control, lower insulin requirement, and increase insulin sensitivity (4-7). Several observational studies have also suggested that soy intake was associated with improved glycemic control or lowered risk of diabetes (8) (9) (10) (11) . A recently published cross-sectional study reported that a higher intake of soy products decreased risk of type 2 diabetes in overweight Japanese women, and the odds ratios for the lowest to highest quintiles of soy intake were 1.00, 0.78, 0.79, 0.62, and 0.89, respectively (11) . A prospective study by Villegas et al (10) also reported a significant lower relative risk of 0.53 (95% CI: 0.45, 0.62) of type 2 diabetes in Chinese women in the upper quintile of soybean intake compared with Chinese women in the lower quintile of soybean intake.
Encouraging findings from animal (4-7) and observational studies (8) (9) (10) (11) have led many researchers to hypothesize that soy intake may be beneficial for glucose and insulin management. Data from human clinical trials that evaluated the possible beneficial effects of isoflavone-rich soy products on glycemic control and insulin sensitivity have generated mixed findings. Some studies showed that soy products and foods significantly improve glycemic control (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , whereas others observed no significant effect (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . This inconsistency could be due to a number of possible reasons. A wide variety of soy products, such as traditional soy foods, isolated soy protein, soy extracts, or purified isoflavones, and a variety of controls have been used (34) . Varied amounts and compositions of protein and isoflavones in soy products and the menopausal status of participants, study duration, baseline health status of participants, intervention adherence, and degree to which dietary intake is controlled may have contributed to variations in studies.
To our knowledge, findings of soy intake on the management of glucose and insulin were not conclusive, and these data have not been systematically evaluated. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to quantitatively evaluate the overall effect of soy on measures of glycemic control. The aim of this meta-analysis was to determine optimal soy sources to improve glycemic control and identify priorities for future research.
METHODS

Search strategy
PubMed (35) . We also checked reference lists of original studies or reviews for additional publications.
Study selection
Studies were selected for analysis if they met the following criteria: 1) adult subjects ingested soy foods or products for !4 wk; 2) the study was an RCT with either a parallel or a crossover design; 3) the initial (baseline) or endpoint values for fasting glucose or insulin or their difference and their SD or SE or 95% CI of each group were available; 4) the study used a concurrent control group; the difference between the treatment and control groups was soy isoflavones, soy protein (with or without isoflavones), or whole soy foods or a soy diet. The eligible treatments and controls were a) whole soy foods or soy in the treatment diets that were replaced with usual foods, milk, or animal products in the control diets, b) isolated or concentrated soy protein (with or without isoflavones) compared with milk or animal protein, and c) purified isoflavones compared with inactive ingredients (such as starch and cellulose); 5) the study was a unifactorial study (ie, soy products were not mixed with other potentially active ingredients or factors); and 6) trials with isoflavones extracted from nonsoy source were excluded.
Data extraction and quality assessment
Data were collected by a piloted data extraction form on authors, years, participants, countries of origin, study designs, types of intervention, outcomes, and trial quality and durations. Primary outcome measures were the net changes in fasting glucose and insulin concentrations, and the secondary outcome included changes in the homeostatic model assessment of insulin resistance (HOMA-IR) and glycated hemoglobin (Hb A 1c ) and 2-h glucose and insulin concentrations. The isoflavone dose was calculated in aglycone equivalents (glycoside concentrations were multiplied by 0.6). In the 4 studies with soy-based dietary interventions that did not provide isoflavone contents, we estimated isoflavone amounts on the basis of contents of common isoflavones in traditional soy foods with '3.5 mg isoflavones/1g soy protein (36) .
The quality of RCTs was assessed by allocation concealment, randomization, masking (participants and outcome assessor), compliance, withdrawals, and intention-to-treat analysis. Trials were considered to be at low risk of bias if allocation concealment and blinding of participants and outcome assessors were all coded yes, a compliance assessment was done, and the number of dropouts and reasons for dropout were reported. If !3 quality criteria were not met, the study was classified as having high risk of bias; others were classified as having moderate risk of bias.
Statistical analyses
A meta-analysis was performed with RevMan software (version 4.2.8; The Cochrane Collaboration, Oxford, United Kingdom). Treatment effects were defined as mean differences between changes in outcomes in subjects who consumed soy foods and changes in outcomes in subjects who consumed control diets. Pooled estimated effects were calculated by assigning each study a weight of the reciprocal of its variance. For crossover trials, mean net changes for outcomes were calculated as differences in values at the end of intervention and control phases. For parallel trials, if variances for differences were not reported, they were calculated by using variances at baselines and ends of trials according to the method of Follmann et al (37) in which a correlation coefficient of 0.5 between initial and final values was assumed. Heterogeneity was assessed by using I 2 to quantify the degree of inconsistency in studies (38) . We presented the results on the basis of a random-effects model when the test for heterogeneity of the total population was significant. Otherwise, the results of a fixed-effects model were presented.
To explore the possible influence of covariates on net changes, subgroup analyses were conducted to evaluate the effects of the following factors on primary outcomes (ie, fasting glucose and insulin concentrations): soy-product types, dosages of soy protein and isoflavone, population characteristics, study duration, and initial fasting glucose concentrations of participants. Sensitivity analyses were also performed to examine the influence of various exclusion criteria on the overall effect sizes such as the quality of trials (with the elimination of trials rated with high risk of bias), menopausal status, and weight changes during the study.
To examine potential publication biases, we plotted SEs of the studies against their corresponding effect sizes. We assessed the publication bias by using funnel plots and Egger's linear regression method to measure the funnel-plot asymmetry. Stata (version 11.0; StataCorp LP, College Station, TX) was used for analyses. If a publication bias was indicated, the effect of such a bias was assessed with the fail-safe number method.
RESULTS
Identification of relevant studies
Detailed processes of the study selection are shown in Figure  1 . The search of literature provided a total of 292 reports. Of these, 254 reports were discarded because of the repetition of citations or because they were clearly not eligible after a review of titles and abstracts. Two additional articles were discarded because full texts were not available (39, 40) . The remaining 36 articles with full texts were examined in more detail. Among them, 2 trials, one study that compared soy isoflavones with estrogen (16) , and one study that compared soy protein that contained isoflavones with cellulose (20) , were excluded because of the difficulty in interpreting the results without a true placebo control. Seven studies were excluded because of a multifactorial intervention in which the independent effects of soy could not be separated or possible interactions might have occurred among intervention factors (18, (41) (42) (43) (44) (45) (46) . Thus, 27 studies were selected.
Subjects in one study were divided into 2 subgroups on the basis of their baseline blood pressures, and subgroup results, but not overall results for fasting glucose, were reported; thus, we treated the study as 2 comparisons (47). One study had 3 groups with one group that consumed a very-low-fat diet (48) ; only the other 2 groups that consumed a usual diet were selected for analysis. Three studies (19, 49, 50) had 2 dosages of isoflavones to avoid the double use of the control group; only the outcome of higher dosage was used for analysis. For studies that reported interim-study measurements, we used measurements from the full-study period for analysis (28, (51) (52) (53) . For studies that included .2 comparisons, to avoid the duplication of subjects for analysis, only 2 groups were selected for each run of analysis (15, 19, 24, 28) .
We detected a significant heterogeneity in fasting glucose concentrations with the inclusion of trials that used genistein as supplements (13, 17, 21) . The exclusion of these 3 trials of genistein removed the statistical heterogeneity. Therefore, the 3 studies that used genistein as supplements were excluded (13, 17, 21) . Thus, a total of 24 studies that involved 29 comparisons and 1518 subjects were finally identified for inclusion in the metaanalysis.
Characteristics of the studies
The characteristics of studies that met the criteria for analysis are shown in Table 1 . Ten studies applied isoflavone extracts as supplements, 9 studies included whole soy foods into the diet, and 5 studies compared the isolated soy protein that contained isoflavones with milk or animal protein. The soy-protein content ranged from 0 to 40 g soy protein/d, and the isoflavone content ranged from 36 to 132 mg isoflavones/d. Eighteen studies focused on women, and most of these studies (14 of 18 studies) were in postmenopausal women. Subjects in 6 studies had elevated fasting glucose concentrations (!6.0 mmol/L) at baseline (3 studies were in diabetic patients, 1 study was in patients with stroke, 1 study was in prediabetic women, and 1 study was in subjects with metabolic syndrome). Most studies (15 of 24 studies) used a parallel design. The trials varied in length from 4 to 52 wk. One-half of the studies (12 of 24 studies) followed a low-energy or low-fat diet. Most studies, except for 3 studies, reported similar weight changes for subjects who ingested the intervention or control diets.
Quality of included studies
The study quality of the 24 included RCTs varied. Most studies that included a soy diet as one of treatments were not blinded. Allocation concealment was adequate in 14 studies, unclear in 8 studies, and not done in 2 studies. Fourteen studies masked participants, and 12 studies masked outcome assessors. Compliance was assessed in 20 studies but was unclear or not done in 4 studies. All but one study reported dropouts and reasons for dropout. Eleven studies were judged to be at low risk of bias (Table 1) .
Overall effect of soy intervention on glycemic control and insulin sensitivity
As shown in Table 2 , soy intake did not significantly affect the change of glycemic variables. We noted significant betweenstudy heterogeneity in the effects of soy on fasting insulin concentrations (I 2 = 62.7%) and HOMA-IR (I 2 = 75.7%) but not in fasting glucose, Hb A 1c , and 2-h glucose and insulin concentrations. A total of 19 trials reported data on fasting glucose concentrations. Soy intake did not significantly affect the change of fasting glucose concentrations, and the pooled estimated change in fasting glucose concentrations was 20.69 mg/dL (95% CI: 21.65, 0.27 mg/dL; P = 0.16) by the fixed-effects model ( Figure 2) . Nineteen trials reported data on fasting insulin concentrations, and the pooled estimated effect was 20.18 lU/mL (95% CI: 20.70, 0.34 lU/mL; P = 0.50) by the randomeffects model (Figure 3) . Six studies reported the results on HOMA-IR, and the pooled estimated mean difference was 20.11 (95% CI: 20.27, 0.06; P = 0.21) (Figure 4 ). Four studies detected Hb A 1c concentrations, and 2 studies examined 2-h postchallenge glucose and insulin concentrations; all changes were shown to be nonsignificant.
Sensitivity and subgroup analysis
The results of the sensitivity analysis on fasting glucose and insulin concentrations showed that the pooled effects remained nonsignificant when analyses were limited to high-quality trials, A usual diet was similar to a conventional diet; low-fat, low-energy, or heart-healthy diets contained less amounts of energy or fat than in a usual diet; and a hemodialysis diet had 35% fat, 1-2 g protein
, and 134-147 kJ energy
Two different dosages of isoflavones were applied in this study.
postmenopausal women, and trials with similar weight changes during studies. Subgroup analyses ( [20. 79 mg/dL (95% CI: 22.10, 0.51 mg/dL)] (P = 0.005 for subgroup difference). There were no statistically significant differences in pooled effects in subgroups stratified by study designs (parallel or crossover), soy protein and isoflavones dosages, basal glucose concentrations, ethnic groups, and durations and background diets.
Nineteen of the 24 trials reported data on fasting insulin concentrations, as shown in Table 4 . Differences in soy-product types, study designs, durations, ethnic groups, soy protein and isoflavones dosages, and background diets did not appear to significantly influence pooled mean differences in fasting insulin concentrations.
Publication bias
The publication bias of trials was examined by analyzing funnel plots and Egger's regression tests. The funnel plots were symmetrical (data not shown), and Egger's regression test suggested no significant asymmetry for the overall effect estimation of fasting glucose and fasting insulin concentrations (P = 0.126 and 0.451, respectively).
DISCUSSION
This meta-analysis of 24 RCTs did not indicate a significant efficacy of soy intake in the improvement of fasting glucose and insulin concentrations. The Evidence of a soy effect on other glycemic variables such as Hb A 1c and 2-h postchallenge glucose The current analyses showed some inconsistent effects of soy intake on glycemic measures in subgroups. The subgroup analysis by soy source suggested that the consumption of whole soy foods or a soy diet rather than purified isoflavones or isolated soy protein was associated with a significant decrease in fasting glucose concentrations. These results concurred with previous findings that the purified isoflavones or isolated soy protein were not as effective as intact soy foods on the improvement of cardiovascular disease risks (15, 52, 59) . The favorable changes could possibly be attributable to the presence of other components of soy (eg, soy fiber, saponin, polysaccharides, phytosterol, and unsaturated fatty acid) or their interactions other than to soy protein or isoflavones alone (60) . It has been reported that different processing procedures in the preparation of soy products affect the intactness of protein subunits or modify soy-associated isoflavones or some other components in soy protein, which might be crucial for the biological functions of soy (61, 62) . However, the clinical implications of these relatively modest changes are unclear and require confirmation in future studies.
Our study has several strengths. First, the relatively large number of pooled participants allowed us a greater statistical power to detect a small treatment effect. Second, to avoid double counting of control patients, only one treatment group for each trial was used in the calculation of the pooled effect if a study had !2 treatment groups. Third, results were unlikely to be because of publication bias. The Egger's regression tests suggested no significant asymmetry of the funnel plot for the overall effect estimation of mean differences in fasting glucose or insulin concentrations.
There were weaknesses of the available data. Measures for glycemic control or insulin sensitivity were not primary outcomes in the majority of trials included in the meta-analysis. It was reasonable to consider that the null findings of secondary outcomes may not have always been published. However, the symmetry testing of the funnel plot did not indicate a notable publication bias in this meta-analysis. In addition, most studies reported only fasting glucose and fasting insulin concentrations, and there was a lack of other important variables for glycemic control and insulin sensitivity. Previous data indicated that the measurement of glycated proteins, such as amounts of Hb A 1c , was a reliable method for assessing long-term glycemic control (63) , and postchallenge glucose concentrations were more strongly associated with cardiovascular diseases than fasting variables (64) . However, in this meta-analysis, only 6 studies reported the effect of soy on HOMA-IR, 4 studies reported on Hb A 1c concentrations, and 2 studies reported on postchallenge variables. Future studies that report on a more comprehensive set of indicators for glycemic control and insulin sensitivity are necessary.
Although a favorable change on fasting glucose and insulin concentrations was observed in studies that used whole soy foods or a soy diet, concerns remained on the methodologic validity of these studies because often the study design could not accommodate adequate blinding. In addition, the soy-based diets included a wide range of isoflavone content and other nonquantitated matrix compounds. It is possible that other active components contained in these foods or their interactions with isoflavones might have contributed to the beneficial effects of whole soy foods or a soy diet. However, the inclusion of these studies in the current meta-analyses provided an additional perspective to the overall effect of soy, and in the subgroup analyses, clearer evidence of the key drivers may have been suggested.
In this meta-analysis, a considerable heterogeneity was observed in the net change of fasting insulin. The clear heterogeneity implied that the effect of soy on fasting insulin concentrations was not uniform, which made it difficult to draw firm conclusions from 1 Numbers of participants in the treatment and control groups. 2 P for trend analysis. There was no significant dose-response relation for the net change in fasting glucose concentrations on the basis of P for trend analysis and the univariate meta-regression model.
3 Low-fat/energy control diet contained less energy or fat than a usual diet.
the data about the existence of effects. Subgroup analyses by study designs, durations, treatment dosages, and population characteristics could not explain the source of heterogeneity. The residual heterogeneity of fasting insulin concentrations could have possibly been because of other between-study variations such as the different methods used for insulin assay. In this meta-analysis, 11 of the 19 included studies reported the methods for insulin assay (6 studies used radioimmunoassays, 3 studies used an enzyme-linked immunosorbent assays, and 2 studies used chemiluminescent assays). Although the use of a standardized mean difference for the pooled effect did not reduce the heterogeneity in the main results, we additionally conducted a subgroup analysis by methods for insulin assays. The results showed no significant heterogeneity in each subgroup of the 3 methods, which implied that the diverse methods for insulin assays could possibly be an important source of the heterogeneity in fasting insulin. Future studies that use a standardized assay for insulin are warranted (65) . Various statistical methods for the calculation of variances of mean differences may possibly contribute to the heterogeneity of pooled effect sizes. In the current analysis, 6 studies (25, 28, 48, 51, 52, 55) directly reported the data on changes (or change percentage) and variances of fasting insulin concentrations between groups; thus, for the remaining studies, we had to calculate the mean differences and corresponding variances from the baseline and endpoint data according to the method of Follmann et al (37) . The different origin of the data on the mean difference 3 P for trend analysis. There was no significant dose-response relation for the net change in fasting insulin concentrations on the basis of P for trend analysis and the univariate meta-regression model. 4 Low-fat/energy control diet contained less energy or fat than a usual diet.
and variance may produce heterogeneity and affect the precision of the pooled effect size. However, we repeated the analyses by replacing the original data on changes and variances of the 6 studies with the calculated data by using the method of Follmann et al (37) , and the overall pooled effects did not materially change. Thus, the 2 assessment methods for variances of mean differences may not have substantially affected the estimated pooled effect of soy on fasting insulin concentrations in this metaanalysis.
In most clinical trials with soy foods or soy protein as the treatment, milk products or milk protein was always selected as the placebo control. Several observational studies have suggested that dairy products may have active biological properties relevant to lowering risk of diabetes and metabolic syndrome (66, 67) . However, these effects have not been confirmed in clinical trials (68) . We further performed an independent analysis to examine the possible placebo effect of milk products. However, the pooled estimated effects between after and before placebo treatment indicated that no placebo effects existed in this meta-analysis (data not shown).
In conclusion, soy intake did not show a notably favorable effect on the reduction of fasting glucose and insulin concentrations, although subgroup analyses showed a favorable change in fasting glucose concentrations in trials that used whole soy foods or a soy diet. Significant heterogeneity was noted in the results of fasting insulin concentrations and HOMA-IR. Additional well-reported RCTs that are specifically designed to evaluate the soy effect on a set of comprehensive clinical outcomes on glucose-insulin management are required.
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